immatics
provides
update
cell
therapy
program
targeting
tumor
microenvironment
nasdaq
imtx
tuebingen
germany
houston
texas
globe
newswire
cell
therapy
program
directed
novel
tumor
target
exon
prevalently
expressed
high
copy
numbers
tumor
stroma
across
many
solid
cancers
two
tcr
candidates
designed
using
immatics
proprietary
platform
demonstrates
high
specificity
potency
one
candidates
shows
full
functionality
also
cells
without
requirement
submission
ind
application
fda
remains
track
tuebingen
germany
houston
texas
september
immatics
nasdaq
imtx
immatics
biopharmaceutical
company
active
discovery
development
cell
redirecting
cancer
immunotherapies
today
provided
update
fourth
cell
therapy
program
designed
address
novel
target
exon
highly
expressed
stroma
large
number
solid
tumors
immatics
discuss
preclinical
data
hanson
wade
digital
week
september
th
preclinical
data
highlights
exon
protein
predominantly
expressed
tumor
stroma
multiple
solid
cancers
including
pancreatic
cancer
breast
cancer
gastric
cancer
sarcoma
esophageal
cancer
cell
lung
cancer
squamous
head
neck
cancer
colorectal
cancer
mesothelioma
ovarian
cancer
others
prevalence
estimates
cancer
types
range
tumor
stroma
target
peptide
derived
exon
high
copy
numbers
per
cell
identified
immatics
proprietary
mass
spectrometry
platform
different
tcrs
peptide
systematically
evaluated
using
immatics
platform
tcr
characterization
engineering
validation
two
tcr
candidates
selected
tcr
candidates
demonstrated
promising
preclinical
properties
including
high
avidity
specificity
towards
tumor
cells
based
screening
toxicity
additional
preclinical
studies
done
close
collaboration
jim
riley
professor
microbiology
university
pennsylvania
product
candidates
showed
tumor
eradication
vitro
vivo
physiological
target
expression
levels
one
two
tcr
candidates
showed
full
target
recognition
engaged
cells
without
need
based
recent
studies
immatics
believes
additional
activation
cells
potentially
favorable
induction
maintenance
responses
solid
cancers
completion
ongoing
final
evaluation
target
tcr
candidates
immatics
expects
submit
investigational
new
drug
ind
application
us
food
drug
administration
fda
program
steffen
walter
chief
technology
officer
immatics
commented
solid
tumors
develop
complex
microenvironment
tumor
stroma
plays
crucial
role
tumor
initiation
progression
metastasis
providing
protective
defense
layer
body
immune
system
taking
apart
tumor
defense
network
novel
highly
potent
tcrs
directed
tumor
stroma
presents
promising
opportunity
address
hard
treat
solid
immatics
program
immatics
fourth
program
targets
tumor
stroma
designed
disrupt
tumor
microenvironment
rigid
stroma
immunosuppressive
microenvironment
solid
tumors
pose
significant
challenge
cell
accessibility
activity
targeting
compartment
could
provide
novel
approach
many
solid
tumors
immatics
selected
two
product
candidates
program
following
initial
discovery
novel
complex
target
using
immatics
proprietary
platform
design
right
tcrs
using
platform
target
present
high
copy
numbers
tumor
stroma
part
exon
protein
extracellular
matrix
component
expressed
predominantly
tumor
stroma
cells
far
lower
extent
healthy
tissues
immatics
act
programs
immatics
clinical
product
class
personalized
approach
patients
advanced
solid
cancers
patient
cells
genetically
modified
express
novel
proprietary
tcr
cancer
target
infused
back
patient
programs
already
clinical
studies
solid
tumor
indications
us
germany
immatics
latest
proprietary
manufacturing
processes
designed
generate
cell
product
candidates
within
six
day
manufacturing
window
deliver
highly
proliferative
cells
capability
infiltrate
patient
tumor
function
challenging
solid
tumor
microenvironment
process
designed
rapidly
produce
younger
cells
capable
serial
killing
tumor
cells
vitro
immatics
advancing
act
concept
beyond
individualized
manufacturing
product
class
developed
generate
cellular
therapies
information
clinical
trials
found
following
links
ends
notes
editors
immatics
immatics
combines
discovery
true
targets
cancer
immunotherapies
development
right
cell
receptors
goal
enabling
robust
specific
cell
response
targets
deep
foundation
pipeline
adoptive
cell
therapies
tcr
bispecifics
well
partnerships
global
leaders
pharmaceutical
industry
committed
delivering
power
cells
unlocking
new
avenues
patients
fight
cancer
regular
updates
immatics
visit
also
follow
us
twitter
linkedin
statements
certain
statements
press
release
may
considered
statements
statements
generally
relate
future
events
immatics
future
financial
operating
performance
example
statements
concerning
timing
product
candidates
immatics
focus
partnerships
advance
strategy
statements
cases
identify
statements
terminology
may
expect
intend
estimate
anticipate
believe
predict
potential
continue
negatives
terms
variations
similar
terminology
statements
subject
risks
uncertainties
factors
could
cause
actual
results
differ
materially
expressed
implied
forward
looking
statements
statements
based
upon
estimates
assumptions
considered
reasonable
immatics
management
inherently
uncertain
new
risks
uncertainties
may
emerge
time
time
possible
predict
risks
uncertainties
factors
may
cause
actual
results
differ
materially
current
expectations
include
limited
various
factors
beyond
management
control
including
general
economic
conditions
risks
uncertainties
factors
set
forth
filings
securities
exchange
commission
sec
nothing
presentation
regarded
representation
person
statements
set
forth
herein
achieved
contemplated
results
statements
achieved
place
undue
reliance
statements
speak
date
made
immatics
undertakes
duty
update
statements
attachments
information
please
contact
media
inquiries
gretchen
schweitzer
jacob
verghese
phd
trophic
communications
phone
immatics
investor
relations
contact
john
graziano
solebury
trout
phone
jgraziano
immatics
anja
heuer
corporate
communications
phone
media
jordan
silverstein
head
strategy
phone
investorrelations
